Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Cardiac Safety Could Be Distinguishing Point For Sunovion's New Antipsychotic Latuda

Nov 08 2010

• By Martin Berman-Gorvine

Related Content

Dainippon Sumitomo Submits Lurasidone NDA, Preps For Marketing Scramble

Jan 06 2010

Dainippon Sumitomo Awakes To The U.S. Market And Buys Sepracor For $2.6 Billion

Sep 03 2009

FDA's U-Turn On Fanapt: Comparative Assessments Must Have Clinical Meaning

Jul 01 2009

Additional Topics

BioPharmaceutical

More from Archive

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window